Real-world Treatment Outcomes of the EXTREME Regimen as First-line Therapy for Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck: A Multi-center Retrospective Cohort Study in Japan
Real-world Treatment Outcomes of the EXTREME Regimen as First-line Therapy for Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck: A Multi-center Retrospective Cohort Study in Japan
复制标题
DOI：
10.21873/anticanres.13898
复制
发表时间：
2019-12-01
影响因子：
2
通讯作者：
Oridate, Nobuhiko
中科院分区：
文献类型：
--
作者：
Sano, Daisuke;Fujisawa, Takuo;Oridate, Nobuhiko
背景/目的：这项日本多中心回顾性研究旨在检查EXTREME方案作为复发性/转移性头颈部鳞状细胞癌（R/M SCCHN）一线治疗的真实治疗结局。患者和方法：共分析了100例接受EXTREME方案作为一线治疗的R/M SCCHN患者。对治疗结果进行评价，以比较患者和治疗特征与总生存率。结果如下：与使用顺铂的患者相比，使用卡铂为基础的EXTREME方案治疗的患者显示出相似的总生存率，且不良反应较少。在EXTREME方案后接受二线治疗的患者中，进展后生存期显著长于未接受二线治疗的患者。结论：卡铂为基础的EXTREME方案与顺铂为基础的EXTREME方案相比，具有更好的可行性和相似的疗效。此外，后续治疗线有助于改善R/M SCCHN患者的生存率。
Background/Aim: This Japanese multiple-center retrospective study aimed to examine the real-world treatment outcomes of the EXTREME regimen as a first-line therapy for recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN). Patients and Methods: A total of 100 R/M SCCHN patients treated with the EXTREME regimen as first-line therapy were analyzed. The treatment outcomes were evaluated to compare patient and treatment characteristics with overall survival. Results: Patients treated with carboplatin-based EXTREME regimen showed similar overall survival with less adverse effects compared to that of patients using cisplatin. The post-progression survival was significantly longer in patients treated with second-line treatment following the EXTREME regimen than in those without second-line treatment. Conclusion: The carboplatin-based EXTREME regimen was more feasible with similar treatment outcomes compared to cisplatin-based EXTREME regimen. In addition, subsequent lines of therapy contributed to improvement of survival for R/M SCCHN patients.